Group items tagged

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, comprising Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau.

Diabetic foot ulcers (DFUs) are a common complication of diabetes. With the increasing prevalence of diabetes across all markets the number of patients suffering from DFUs is also expected to rise. The global DFU therapeutics market is set to enter an exciting phase with the potential launch of three wound-healing agents in the next five years. The first two topical antibacterial are also expected to be launched in the US and the five major EU markets. With the advent of these new product launches, the size of the DFU market is expected to grow substantially by 2017.

Emerging players with potentially strong product portfolio is expected to capture the global Xerosis treatment market. It is essential for the marketers to design effective counter-strategies to gain competitive advantage. A promising pipeline indicates mergers and acquisitions. Devising corrective measures for pipeline projects would also require an in-depth understanding of the Xerosis pipeline depth and focus of indication therapeutics.

An in-depth analysis of the diverse types of therapeutics under development for T-Cell Lymphomas and identification of emerging players with potentially strong product portfolio assists marketers design effective counter-strategies to gain competitive advantage. Latest updates provide insights into the most attractive projects with emerging opportunities to enhance and expand business potential and scope.

Novel approaches to treat infection is growing as the need is urgent. Misuse or overuse of antibiotics accelerated Anti-Microbial Resistance (AMR) and has resulted in the emergence of super bugs which are posing life threatening challenges worldwide. Novel approaches are immediately required to combat these super infections warranting need for new classes of antibiotics and other preventive/therapeutic approaches.

This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Global Markets Directs, Dengue - Pipeline Review, H1 2014, provides an overview of the Dengues therapeutic pipeline. It also enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.

Treating refractory hematological malignancies unfold a host of competition and commercial opportunities. Approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts attract swarming competition. There is severe competition amongst the companies to launch new therapies for this indication. Companies leading in the race to launch such therapies include Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene.

The German chronic heart failure (CHF) therapeutics market was worth approximately USD 484.7 million in 2012, with a projected compound annual growth rate (CAGR) of 2.4%, to reach a total of USD 614.8 million in 2022. The launch of Novartis' novel combination drug, LCZ-696 in 2015 will mark the first entrance of a novel branded CHF drug in the past five years, boosting the overall market size considerably till 2022.

The non-existence of effective vaccine against HCV leads the healthcare market in United States to be driven by therapeutics. Vertexs Incivek was amongst the first DAA HCV therapies launched in the US and is the current market leader. Inciveks improved efficacy over the previous standard of care in the treatment of the most prevalent HCV genotype in the US, HCV GT1, which enabled the drug to quickly capture the market. Adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.